The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Official Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Study ID: NCT03481556
Brief Summary: This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Dana Farber Cancer Institute, Boston, Massachusetts, United States
The Ohio State University, Columbus, Ohio, United States
Fakultní nemocnice Brno, Brno, , Czechia
Fakultní nemocnice Hradec Králové, Hradec Králové, , Czechia
Fakultní nemocnice Ostrava, Ostrava, , Czechia
Všeobecná fakultní nemocnice, Praha, , Czechia
Hôpital Morvan, Brest, , France
Centre Jean Bernard - Clinique Victor Hugo, Le Mans, , France
Hôpital privé du Confluent, Nantes, , France
Centre Hospitalier Lyon Sud, Pierre-Bénite, , France
Centre Hospitalier Universitaire Institut Gustave Roussy, Villejuif, , France
Hospital Universitai Germans Trias i Pujol, Badalona, , Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Complejo Hospitalario de Salamanca, Salamanca, , Spain
Hospital Universitario Marques de Valdecilla, Santander, , Spain